Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma

被引:30
作者
Connelly, Philip W. [1 ,2 ,3 ]
Maguire, Graham F. [1 ]
Picardo, Clive M. [1 ,2 ]
Teiber, John F. [4 ]
Draganov, Dragomir [5 ]
机构
[1] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ Toronto, Med Lab & Pathobiol, Toronto, ON, Canada
[4] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Epidemiol, Dallas, TX USA
[5] WIL Res Labs LLC, Dept Metab, Ashland, OH USA
关键词
Western blot; quantitation; lipoproteins; high density lipoproteins;
D O I
10.1194/jlr.D700022-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Paraoxonase 1 (PON1) requires calcium for activity and is inactivated in the presence of EDTA. Because of this, studies to date have used serum or heparinized plasma for both activity and mass assays of PON1. Whole serum and EDTA plasma were analyzed by SDS-electrophoresis and Western blot using anti-PON1 monoclonal antibody 4C10. Because PON1 has one disulfide and one free cysteine residue, the samples were reduced with dithiothreitol before electrophoresis. Western blot identified a major PON1 band with a molecular mass of similar to 45 kDa and two minor bands of similar to 40 and 35 kDa in both serum and EDTA plasma. This established that PON1 is inactive, but structurally intact, in EDTA plasma and suggested that a mass assay could be developed based on SDS-electrophoresis and Western blot. Linearity was established for plasma and for a PON1 standard. Quantification was based on the major PON1 band at 45 kDa. The correlation between serum and plasma PON1 mass was 0.9553. The between-run variation was determined with a serum pool to be 7.8%. The mass of PON1 in serum was significantly correlated with arylesterase activity (r = 0.85).
引用
收藏
页码:245 / 250
页数:6
相关论文
共 26 条
[1]   SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]   Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences [J].
Aviram, M ;
Rosenblat, M .
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) :393-399
[3]   Serum paraoxonase after myocardial infarction [J].
Ayub, A ;
Mackness, MI ;
Arrol, S ;
Mackness, B ;
Patel, J ;
Durrington, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :330-335
[4]   Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation [J].
Boemi, M ;
Leviev, I ;
Sirolla, C ;
Pieri, C ;
Marra, M ;
James, RW .
ATHEROSCLEROSIS, 2001, 155 (01) :229-235
[5]   Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression [J].
Brophy, VH ;
Jampsa, RL ;
Clendenning, JB ;
McKinstry, LA ;
Jarvik, GP ;
Furlong, CE .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (06) :1428-1436
[6]   TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease [J].
Carlson, Christopher S. ;
Heagerty, Patrick J. ;
Hatsukami, Thomas S. ;
Richter, Rebecca J. ;
Ranchalis, Jane ;
Lewis, Julieann ;
Bacus, Tamara J. ;
McKinstry, Laura A. ;
Schellenberg, Gerard D. ;
Rieder, Mark ;
Nickerson, Deborah ;
Furlong, Clement E. ;
Chait, Alan ;
Jarvik, Gail P. .
JOURNAL OF LIPID RESEARCH, 2006, 47 (05) :1014-1024
[7]   Modulation of paraoxonase (PON1) activity [J].
Costa, LG ;
Vitalone, A ;
Cole, TB ;
Furlong, CE .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (04) :541-550
[8]  
Garin M.C., 1997, J CLIN INVEST, V99, P62
[9]   QUANTIFICATION OF HUMAN SERUM PARAOXONASE BY ENZYME-LINKED IMMUNOASSAY - POPULATION DIFFERENCES IN PROTEIN CONCENTRATIONS [J].
GARIN, MCB ;
ABBOTT, C ;
MESSMER, S ;
MACKNESS, M ;
DURRINGTON, P ;
POMETTA, D ;
JAMES, RW .
BIOCHEMICAL JOURNAL, 1994, 304 :549-554
[10]  
Ikeda Y, 2007, CLIN NEPHROL, V67, P358